

Tuberculosis profile: Sri Lanka

Population 2021: 22 million

Estimates of TB burden*, 2021

	Number	(Rate per 100 000 population)
Total TB incidence	14 000 (9 900-18 000)	63 (46-83)
HIV-positive TB incidence	100 (62-150)	0.46 (0.29-0.67)
MDR/RR-TB incidence**	91 (0-200)	0.42 (0-0.94)
HIV-negative TB mortality	760 (680-830)	3.5 (3.1-3.8)
HIV-positive TB mortality	23 (14-35)	0.11 (0.06-0.16)

Estimated proportion of TB cases with MDR/RR-TB*, 2021

New cases	0.5% (0.11-1.5)
Previously treated cases	3% (1.9-4.5)

Universal health coverage and social protection*

TB treatment coverage (notified/estimated incidence), 2021	48% (36-66)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2021	6% (4-8)

TB case notifications, 2021

Total new and relapse	6 551
- % tested with rapid diagnostics at time of diagnosis	24%
- % with known HIV status	>100%
- % pulmonary	71%
- % bacteriologically confirmed [^]	79%
- % children aged 0-14 years	2%
- % women (aged ≥15 years)	36%
- % men (aged ≥15 years)	62%
Total cases notified	6 771

TB/HIV care in new and relapse TB patients, 2021

	Number	(%)
Patients with known HIV status who are HIV-positive	48	0.73%
- on antiretroviral therapy	23	48%

Drug-resistant TB care**, 2021

% of bacteriologically confirmed TB cases tested for rifampicin resistance - New cases [^]	35%
% of bacteriologically confirmed TB cases tested for rifampicin resistance - Previously treated cases [^]	96%
Laboratory-confirmed cases - MDR/RR-TB ^{^^}	10
Patients started on treatment - MDR/RR-TB ^{^^^}	9
Laboratory-confirmed cases - pre-XDR-TB or XDR-TB ^{^^}	0
Patients started on treatment - pre-XDR-TB or XDR-TB ^{^^^}	0
MDR/RR-TB cases tested for resistance to any fluoroquinolone	

Treatment success rate and cohort size

	Success	Cohort
New and relapse cases registered in 2020	83%	7 036
Previously treated cases, excluding relapse, registered in 2020	69%	227
HIV-positive TB cases registered in 2020	73%	33
MDR/RR-TB cases started on second-line treatment in 2019	68%	19
Pre-XDR-TB/XDR-TB cases started on second-line treatment in 2019		0


TB preventive treatment, 2021

% of HIV-positive people (newly enrolled in care) on preventive treatment	39%
% of children (aged < 5 years) household contacts of bacteriologically-confirmed TB cases on preventive treatment	62% (57-68)


Funding for TB

Funding for TB, 2021 (US\$ millions)	4
- % domestic funding	62%
- % international funding	38%


Incidence, New and relapse TB cases notified, HIV-positive TB incidence (Rate per 100 000 population per year)




HIV-negative TB mortality (Rate per 100 000 population per year)




Incidence, Notified cases by age group and sex, 2021



Cases attributable to five risk factors, 2021



Funding for TB (US\$ millions)



* Estimates of TB burden are produced by WHO in consultation with countries. Ranges represent uncertainty intervals.
** RR is TB resistant to rifampicin (R), MDR is TB resistant to R + isoniazid; pre-XDR is TB resistant to R + any fluoroquinolone
^ Calculated for pulmonary cases only
^^ Includes cases with unknown previous TB treatment history
^^^ Includes patients diagnosed before 2021 and patients who were not laboratory-confirmed

Generated 2022-11-28 by the World Health Organization (<https://www.who.int/teams/global-tuberculosis-programme/data>)